Antibody-Drug Conjugate Targeting c-Kit for Resistant Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers with c-Kit mutations, such as gastrointestinal stromal tumors and acute myeloid leukemia, face limitations due to drug resistance and adverse reactions associated with small molecule inhibitors.
Innovation Solution
Development of an antibody-drug conjugate (ADC) that specifically binds to human c-Kit, utilizing a cleavable linker and a microtubule inhibitor moiety to deliver cytotoxic agents directly to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors (imatinib, dasatinib, sunitinib, axitinib) are used to treat c-Kit mutated cancers, then c-Kit activity is inhibited, but drug resistance develops due to mutations at different sites and grade 3/4 adverse reactions increase
Solution Approach 1:
The invention segments the treatment approach by using an antibody-based system rather than small molecules. The antibody component specifically recognizes c-Kit regardless of intracellular mutations, while the drug component provides cytotoxic activity. This segmentation allows the targeting mechanism (antibody binding to extracellular domain) to be independent from the mutation sites (intracellular domain), thereby overcoming drug resistance.
Solution Approach 2:
The antibody acts as an intermediary that bridges the extracellular target recognition and intracellular drug delivery. The antibody binds to the extracellular domain of c-Kit, serving as a mediator that can recognize the target regardless of intracellular mutations, and then delivers the cytotoxic drug to the cancer cell through internalization or other delivery mechanisms.
2Reliability
If small molecule inhibitors are used to treat c-Kit mutated cancers, then c-Kit activity is inhibited, but the rate of grade 3/4 adverse reactions increases
Solution Approach 1:
The invention applies local quality by making the drug delivery localized to cancer cells expressing c-Kit. The antibody component provides specificity by binding only to c-Kit-positive cells, thereby concentrating the cytotoxic effect at the target site while sparing normal tissues. This localized action reduces systemic adverse reactions compared to small molecule inhibitors that distribute throughout the body.
Solution Approach 2:
The invention converts the potential harm of cytotoxic drugs into a beneficial targeted therapy. By coupling the cytotoxic drug to an antibody that specifically recognizes c-Kit, the harmful cytotoxic effect is redirected specifically to cancer cells expressing c-Kit, transforming a potentially harmful non-specific chemotherapy into a targeted therapy with reduced adverse reactions.
3Adaptability or versatility
If ADCs are designed to bind to extracellular domain of target molecules, then they are applicable regardless of intracellular mutations, but the complexity of the conjugate structure increases
Solution Approach 1:
The antibody component of the ADC is designed with universal recognition capability for c-Kit across different mutation types. By targeting the extracellular domain which remains relatively conserved despite intracellular mutations, the ADC achieves universal applicability to various c-Kit mutated cancers, making one conjugate structure effective against multiple mutation types.
Data Source
AI summary
The present invention relates to an antibody-drug conjugate targeting c-Kit and a use thereof.